1117-52-8

Basic information

• Product Name: (5E,9E)-6,10,14-Trimethylpentadeca-5,9,13-trien-2-one
• Synonyms: FARNEZYLACETONE;FEMA 3442;(5E,9E)-6,10,14-Trimethylpentadeca-5,9,13-trien-2-one;(5E,9E)-6,10,14-Trimethyl-5,9,13-pentadecatrien-2-one;5,9,13-Pentadecatrien-2-one, 6,10,14-trimethyl-, (E,E)-;(E,E)-6,10,14-trimethylpentadeca-5,9,13-trien-2-one;(E,E)-farnesylacetone,(5E,9E)-6,10,14-trimethyl-5,9,13-pentadecatrien-2-one,farnesylacetone,;Farnesylaceton
• CAS NO: 1117-52-8
• Molecular Formula: C₁₈H₃₀O
• Molecular Weight: 262.43
• EINECS: 212-097-9
• Product Categories: Cnbio
• Mol File: 1117-52-8.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 372.773 °C at 760 mmHg
• Flash Point: 140.43 °C
• Appearance: /
• Density: 0.88 g/mL at 20 °C(lit.)
• Vapor Pressure: 9.39E-06mmHg at 25°C
• Refractive Index: n20/D 1.481
• Storage Temp.: 2-8°C
• Solubility: DMSO (Sparingly), Ethyl Acetate (Slightly), Methanol (Sparingly)
• Stability: Light Sensitive
• CAS DataBase Reference: (5E,9E)-6,10,14-Trimethylpentadeca-5,9,13-trien-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (5E,9E)-6,10,14-Trimethylpentadeca-5,9,13-trien-2-one(1117-52-8)
• EPA Substance Registry System: (5E,9E)-6,10,14-Trimethylpentadeca-5,9,13-trien-2-one(1117-52-8)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 2
• Hazardous Substances Data: 1117-52-8(Hazardous Substances Data)

Usage

Uses

E,E-Farnesylacetone, is a natural organic compound which is present in many essential oils. It has been shown that, Farnesylacetone inhibits electron transport in isolated rat liver mitochondria.

Definition

ChEBI: A terpene ketone in which an (E,E)-farnesyl group is bonded to one of the alpha-methyls of acetone.

InChI:InChI=1/C18H30O/c1-15(2)9-6-10-16(3)11-7-12-17(4)13-8-14-18(5)19/h9,11,13H,6-8,10,12,14H2,1-5H3/b16-11+,17-13+

Upstream product

• 80868-09-3 (5E,9E)-6,10,14-Trimethyl-3-(toluene-4-sulfonyl)-pentadeca-5,9,13-trien-2-one 
• 59905-15-6 dehydronerolidol 
• 3796-70-1 trans geranyl acetone 
• 50994-69-9 potassium Z-2-methyl-1,3-butadienylsulfinate 
• 86948-89-2 (E)-2-Acetyl-6-(3,7-dimethyl-octa-1,6-diene-3-sulfonyl)-5-methyl-hex-4-enoic acid tert-butyl ester 
• 86948-98-3 3,7-Dimethyl-3-((Z)-2-methyl-buta-1,3-diene-1-sulfonyl)-octa-1,6-diene 
• 92747-33-6 methyl (E)-2-methyl-6-oxo-2-heptenyl carbonate 
• 53254-60-7 3,7-dimethyl-1-(p-toluenesulfonyl)-2(E),6-octadiene 
• 112162-99-9 3-Oxo-butyric acid (E)-1,5,9-trimethyl-1-vinyl-deca-4,8-dienyl ester 
• 86948-99-4 (E)-7-(3,7-Dimethyl-octa-1,6-diene-3-sulfonyl)-6-methyl-hept-5-en-2-one 
• 22842-11-1 (5Ξ,9E)-6,10,14-trimethyl-pentadeca-5,9,13-trien-1-yne 
• 62026-31-7 [3-(2-methyl-[1,3]dioxolan-2-yl)-propyl]-magnesium chloride 
• 502-61-4 (E,E)-alpha-farnesene 
• 18794-84-8 (E)-β-farnesene 

Downstream Products

• 3796-63-2 (E,E,E)-geranylgeranylacetone 
• 50848-64-1 2E,6E,10E-geranylgeranyl bromide 
• 1113-21-9 (6E,10E)-geranyllinalool 
• 80016-61-1 4-(3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenoyl)morpholine 
• 68-26-8 RETINOL 
• 127-47-9 Retinol acetate 
• 1150-17-0 (E)-6-methyl-8-(2,6,6-trimethylcyclohex-1-en-1-yl)oct-5-en-2-one 
• 7541-49-3 3,7,11,15-tetramethyl-2-hexadecen-1-ol 
• 3796-64-3 (5Z,9E,13E)-2-acetyl-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one 
• 6809-52-5 5E,9E,13E-geranylgeranyl acetone 
• 17407-37-3 vitamin E succinate 
• 59-02-9 vitamin E 
• 502-69-2 6,10,14-Trimethyl-2-pentadecanon 
• 13955-75-4 (6S,10R)-6,10,14-trimethylpentadecan-2-one 

Relevant articles and documents

-

-

Biosynthesis of indole diterpenes, emindole, and paxilline: Involvement of a common intermediate

The key step for construction of the carbon skeleton in the indole diterpenes, paxilline, and emindole DA was examined. Intact incorporation of multiply 2H-labeled 3-geranylgeranylindole into two different fungal metabolites proves 3-geranylgeranylindole to be a biosynthetic intermediate. These results give evidence that indole diterpenes are biosynthesized via epoxidation of a common intermediate, and the subsequent cationic cyclization, analogous to those in the steroid biosynthesis.

Preparation method of vitamin A and vitamin A ester

The invention provides a novel method for preparing vitamin A and vitamin A ester with farnesene as a raw material. The method comprises the following steps: reacting farnesene with acetoacetate underthe action of a catalyst to obtain farnesyl keto ester; carrying out a cyclization reaction and a dehydrogenation reaction on farnesene acetone, and then reacting a reaction product with vinyl magnesium halide to generate vinyl alcohol; carrying out a rearrangement reaction on vinyl alcohol to obtain vitamin A; and subjecting the vitamin A to an esterification reaction to obtain the vitamin A ester. The method avoids the defects of the existing processes, and the process line of the method is economical and effective.

SYNTHESIS OF ALKYL 2-ACETYL-5,9,13-TRIMETHYLTETRADECA-4,8,12-TRIENOATES AND DERIVATIVES BY A NON-CONTINUOUS PRODUCTION PROCESS

The present invention relates to the manufacturing of a process of alkyl 2- acetyl-5,9,13-trimethyltetradeca-4,8,12-trienoates and alkyl 2-acetyl-9,13-di- methyl-5-methylenetetradeca-8,12-dienoate as well as 6,10,14-trimethylpenta- deca-5,9,13-trien-2-one and 10,14-dimethyl-6-methylenepentadeca-9,13-dien-2-5 one and 6,10,14-trimethylpentadecan-2-one.

GGA DERIVATIVES

This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives.